産褥出血における第XIII因子補充療法:生物学的根拠から臨床的実装まで
Jeremy W Jacobs1,2, Elizabeth A Abels3, Brian D Adkins4
1Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.
American journal of hematology
|December 31, 2025
まとめ
早期の第XIII因子補充療法は、産褥出血(PPH)による母体死亡を減少させる可能性があります。この研究では、FXIIIを調査します。
科学分野:
- 産科婦人科
- 血液学
- トランスレーショナル・メディシン
背景:
- 産褥出血(PPH)は、予防可能な母体死亡の主な原因です。
- 標準的な介入およびフィブリノーゲン試験は、PPH関連死亡率の減少において限定的な成功を示しています。
- 凝固第XIII因子(FXIII)活性は、妊娠中およびPPH中に低下し、止血における役割を示唆しています。
主な方法:
- SWIFT試験(NCT06481995)は、PPHにおける早期FXIII補充療法に関する最初のランダム化比較試験です。
- 観察研究では、妊娠前のFXIII低下が出血リスクを予測することが示されています。
- 試験管内研究では、FXIII補充が血餅の硬さを回復させることが実証されています。
結論:
- FXIIIは血餅の安定化に重要な役割を果たします。
- 早期FXIII補充療法は、PPHの結果を改善するための有望な戦略です。
- 実装上の課題に対処することは、PPH管理におけるFXIII療法の成功裡な採用のために重要です。
関連する概念動画
Venous Thrombosis III: Interprofessional Care
257
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
257
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Venous Thrombosis IV: Nursing Management
176
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
176
Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K


